A highly immunogenic vaccine against A/H7N9 influenza virus

Vaccine. 2016 Feb 3;34(6):744-9. doi: 10.1016/j.vaccine.2015.12.062. Epub 2016 Jan 4.

Abstract

Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/H7N9 viral challenge suggesting its potential utility as a pandemic vaccine.

Keywords: A/H7N9 influenza vaccine; Adenoviral vector vaccine; Antibody responses; H7HA, cell-mediated immunity; Mouse model; Protective immunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae
  • Animals
  • Antibodies, Viral / blood
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology*
  • Immunity, Cellular*
  • Immunity, Humoral
  • Influenza A Virus, H7N9 Subtype*
  • Influenza Vaccines / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Neutralization Tests
  • Orthomyxoviridae Infections / prevention & control*

Substances

  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Influenza Vaccines
  • hemagglutinin, avian influenza A virus